Treatment with ActRIIB-mFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy

Authors

Jennifer Tinklenberg, Medical College of Wisconsin
Hui Meng, Medical College of Wisconsin
Lin Yang, University of Florida
Fujun Liu, University of Florida
Raymond G. Hoffmann, Medical College of Wisconsin
Mahua Dasgupta, Medical College of Wisconsin
Kenneth P. Allen, Medical College of Wisconsin
Alan H. Beggs, Harvard University
Edna C. Hardeman, University of New South Wales
R. Scott Pearsall, Acceleron Pharma, Inc.
Robert Fitts, Marquette UniversityFollow
Michael W. Lawlor, Medical College of Wisconsin

Document Type

Article

Language

eng

Publication Date

6-2016

Publisher

Elsevier

Source Publication

American Journal of Pathology

Source ISSN

0002-9440

Original Item ID

DOI: 10.1016/j.ajpath.2016.02.008

Comments

NOTICE: this is the author’s version of a work that was accepted for publication in American Journal of Pathology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in American Journal of Pathology, Vol. 186, No. 6 (June 2016): 1568-1581. DOI. © 2016 Elsevier. Used with permission.

Recommended Citation

Tinklenberg, Jennifer; Meng, Hui; Yang, Lin; Liu, Fujun; Hoffmann, Raymond G.; Dasgupta, Mahua; Allen, Kenneth P.; Beggs, Alan H.; Hardeman, Edna C.; Pearsall, R. Scott; Fitts, Robert; and Lawlor, Michael W., "Treatment with ActRIIB-mFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy" (2016). Mathematics, Statistics and Computer Science Faculty Research and Publications. 461.
https://epublications.marquette.edu/mscs_fac/461